EARNINGS: CRISM loss widens as "actively" prepares for phase 2 trial
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Price | 11.00p on 03-10-2025 | at 14:40:06
---|---|
Change | 0.00p 0% |
Buy | 12.00p |
Sell | 10.00p |
Last Trade: | Buy 791.00 at 12.00p |
Day's Volume: | 13,535 |
Last Close: | 11.00p |
Open: | 11.00p |
ISIN: | VGG042401262 |
Day's Range | 11.00p - 11.00p |
52wk Range: | 6.25p - 29.00p |
Market Capitalisation: | £4.40m |
VWAP: | 11.48277p |
Shares in Issue: | 39.96m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Crism Thera (CRTX) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Buy* | 791 | 12.00p | Ordinary |
15:09:41 - 03-Oct-25 |
Buy* | 2,045 | 11.98p | Ordinary |
15:09:15 - 03-Oct-25 |
Buy* | 250 | 12.00p | Ordinary |
14:03:52 - 03-Oct-25 |
Buy* | 30 | 11.08p | Ordinary |
12:05:04 - 03-Oct-25 |
Buy* | 567 | 11.08p | Ordinary |
11:27:11 - 03-Oct-25 |
Buy* | 5,481 | 11.02p | Ordinary |
10:04:17 - 03-Oct-25 |
Buy* | 41 | 12.00p | Ordinary |
08:32:10 - 03-Oct-25 |
Buy* | 2,000 | 11.76p | Ordinary |
08:22:26 - 03-Oct-25 |
Buy* | 2,330 | 11.76p | Ordinary |
08:06:20 - 03-Oct-25 |
Sell* | 68 | 10.925p | Ordinary |
16:11:12 - 02-Oct-25 |
Crism Thera (CRTX) Regulatory News |
||
Date | Source | Headline |
---|---|---|
15th Sep 2025 7:00 am | RNS | Half Year Report |
12th Sep 2025 7:00 am | RNS | Notice of Interim Results and IMC Presentation |
1st Sep 2025 7:00 am | RNS | Approval for phase 2 clinical trial |
26th Aug 2025 4:03 pm | RNS | Result of AGM |
26th Aug 2025 7:00 am | RNS | AGM Statement |
12th Aug 2025 7:00 am | RNS | GMP Manufacture of ChemoSeed |
4th Aug 2025 5:45 pm | RNS | Notice of AGM and EMI Option Plan |
10th Jul 2025 3:04 pm | RNS | Holding(s) in Company |
3rd Jul 2025 7:00 am | RNS | Result of Retail Offer and Additional Placing |
1st Jul 2025 4:41 pm | RNS-R | Update presentation on the IMC platform |